- Home
- MAMA vs BMEA Comparison
MAMA vs BMEA Comparison
Compare MAMA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- BMEA
- Stock Information
- Founded
- MAMA 2010
- BMEA 2017
- Country
- MAMA United States
- BMEA United States
- Employees
- MAMA N/A
- BMEA N/A
- Industry
- MAMA Specialty Foods
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MAMA Consumer Staples
- BMEA Health Care
- Exchange
- MAMA Nasdaq
- BMEA Nasdaq
- Market Cap
- MAMA 290.7M
- BMEA 145.0M
- IPO Year
- MAMA N/A
- BMEA 2021
- Fundamental
- Price
- MAMA $7.67
- BMEA $3.69
- Analyst Decision
- MAMA Strong Buy
- BMEA Buy
- Analyst Count
- MAMA 3
- BMEA 13
- Target Price
- MAMA $10.67
- BMEA $37.25
- AVG Volume (30 Days)
- MAMA 473.3K
- BMEA 1.1M
- Earning Date
- MAMA 12-16-2024
- BMEA 10-29-2024
- Dividend Yield
- MAMA N/A
- BMEA N/A
- EPS Growth
- MAMA N/A
- BMEA N/A
- EPS
- MAMA 0.08
- BMEA N/A
- Revenue
- MAMA $116,468,000.00
- BMEA N/A
- Revenue This Year
- MAMA $18.91
- BMEA N/A
- Revenue Next Year
- MAMA $12.69
- BMEA N/A
- P/E Ratio
- MAMA $91.21
- BMEA N/A
- Revenue Growth
- MAMA 17.20
- BMEA N/A
- 52 Week Low
- MAMA $4.17
- BMEA $3.61
- 52 Week High
- MAMA $9.98
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- MAMA 39.03
- BMEA 23.76
- Support Level
- MAMA $7.55
- BMEA $3.74
- Resistance Level
- MAMA $9.83
- BMEA $4.30
- Average True Range (ATR)
- MAMA 0.46
- BMEA 0.41
- MACD
- MAMA -0.11
- BMEA 0.00
- Stochastic Oscillator
- MAMA 17.27
- BMEA 1.88
About MAMA Mama's Creations Inc.
Mama`s Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in over 8,400 grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.